Kymera Therapeutics develops protein degrader therapeutics using its proprietary Pegasus™ platform to improve targeted protein degradation. The Pegasus platform combines informatics-driven target identification, novel E3 ligases, ternary complex predictive modeling, and degradation tools. Its lead program targets IRAK4, with plans to advance IRAK4 degraders in autoinflammatory, autoimmune, and precision oncology indications. The company is also developing degraders against STAT3 for cancers and chronic diseases involving inflammation and fibrosis. Kymera is led by co-founder and CEO Nello Mainolfi, PhD, with Bruce Booth, DPhil, as co-founder and chairman. Financially, Kymera closed a $102M Series C financing to support its pipeline and development plans. Kymera Therapeutics, founded in 2016 and based in Cambridge, Mass., is advancing targeted protein degradation to create novel therapies. The company’s Pegasus platform integrates informatics-driven target identification, ternary complex predictive modeling, new degradation tools, and novel E3 ligases and ligands. Kymera is focused on degrading dysregulated, disease-causing proteins to address difficult targets across oncology and immunology. Leadership includes president and CEO Laurent Audoly and co-founder and chief technology officer Nello Mainolfi. The company intends to advance its lead assets toward clinical development while progressing its broader therapeutic pipeline in oncology and immunology. Kymera Therapeutics is a Cambridge, MA-based biotechnology company advancing targeted protein degradation to degrade disease-causing proteins rather than inhibit them. Its proprietary integrated degradation platform combines informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company is pursuing a focused set of programs in oncology, immuno-oncology, autoimmune and inflammatory diseases and expects to engage in strategic partnerships with biopharmaceutical companies. Leadership includes co-founder and CTO Nello Mainolfi, Ph.D., and president and CEO Laurent Audoly, Ph.D. Kymera plans to use its Series A proceeds to advance the new therapeutic modality and discover medicines for previously untreatable diseases and expects to nominate its first development candidate next year. Scientific advisors and a board that includes academic and industry figures support the company’s preclinical development efforts.

Total raised

$197M

Funding rounds

3

Latest round

Series C

Latest activity

Mar 2020